- Raised $26M funding round, Jan 2015
- Raised $27.5M funding round, Aug 2008
- Raised $14M funding round led by BNP Paribas, Dec 2020
About
BrainsGate is a medical device company that develops therapies for patients suffering from central nervous system diseases, with a focus on the treatment of acute ischemic stroke. The companys platform technology involves electrical stimulation of the sphenopalatine ganglion, a nerve center known to increase cerebral blood flow. Building on its technology, BrainsGate has developed the Ischemic Stroke System (ISS), in which a miniature electrode is implanted in the roof of the mouth in a minimally invasive bedside procedure performed under local anesthesia and comparable to a dental treatment. In 2008, BrainsGate completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011, the company completed a 300-patient RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multinational, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.
Funding history · 6 rounds · $98.5M total
Q&A
- What is BrainsGate's primary focus?
- BrainsGate is a medical device company that develops therapies for patients suffering from central nervous system diseases, with a focus on the treatment of acute ischemic stroke.
- What is BrainsGate's core technology?
- BrainsGate's platform technology involves electrical stimulation of the sphenopalatine ganglion, a nerve center known to increase cerebral blood flow.
- What is the Ischemic Stroke System (ISS) developed by BrainsGate?
- The Ischemic Stroke System (ISS) is a system in which a miniature electrode is implanted in the roof of the mouth in a minimally invasive bedside procedure, comparable to a dental treatment.
- What is the current status of BrainsGate's clinical trials?
- BrainsGate is currently running the ImpACT-24b, a multinational, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window.
- When was BrainsGate founded?
- BrainsGate was founded in July 2000.
- How many employees does BrainsGate have?
- BrainsGate has 11-50 employees.
- What is BrainsGate's total funding raised to date?
- BrainsGate has raised a total of $98,500,000 USD.
- When was BrainsGate's most recent funding round and who were the lead investors?
- BrainsGate's most recent funding round was in December 2020, with BNP Paribas as a lead investor.
- Which investors participated in BrainsGate's August 2008 funding round?
- Johnson & Johnson Innovation and Agate Medical Investments participated in BrainsGate's August 2008 funding round.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainsgate.com |
|---|---|
| linkedin.com/company/140283 | |
| YouTube | youtube.com/channel/UCuaYZKxRZKbwszkOrEeVmSA |
Identifiers & details
| Founded | 2000-7 |
|---|---|
| Employees (exact) | 19 |
Radar intelligence
Patents
| EPO | 28 |
|---|
Publications (Crossref)
| Works | 6 |
|---|
Web history (Wayback)
| Domain | brainsgate.com |
|---|
Certificate / subdomain footprint
| Subdomains | 5 |
|---|